⌕
Zymeworks BC · ZYME · Nasdaq
Tenet — · insufficient data
Compare
$26.45+0.80%At close
$26.45+0.21 (+0.80%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review since Nov 13, 2026, showing figures confirmed Nov 12, 2026.Under review: these figures were confirmed on an earlier night and are shown while our checks are re-run.

Zymeworks BC (ZYME) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 16, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Zymeworks Announces $200 Million Share Repurchase Authorization

Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and …

● Zacks Investment ResearchNov 9, 2026 · 19:36 ETEARNINGS EXPECTED BY JAN 25
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates

Zymeworks Inc. (ZYME) came out with quarterly earnings of $2.28 per share, missing the Zacks Consensus Estimate of $2.4 per share. This compares to a loss of $0.26 per share a year ago.…

● GlobeNewsWireNov 9, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results

VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, mult…

● Defense WorldNov 2, 2026 · 05:59 ETEARNINGS EXPECTED BY JAN 25
Comparing Vericel (NASDAQ:VCEL) and Zymeworks (NASDAQ:ZYME)

Zymeworks (NASDAQ: ZYME - Get Free Report) and Vericel (NASDAQ: VCEL - Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of th…

● Zacks Investment ResearchOct 29, 2026 · 11:01 ETEARNINGS EXPECTED BY JAN 25
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● MarketBeatOct 27, 2026 · 19:05 ET
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

Zymeworks NASDAQ: ZYME outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its recently announced col…

● Seeking AlphaOct 27, 2026 · 15:30 ET
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript

Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript…

● Business WireOct 27, 2026 · 07:00 ET
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment …

● GlobeNewsWireOct 24, 2026 · 02:30 ETCOMPANY'S OWN WORDS
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multi…

● GlobeNewsWireOct 23, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multi…

● GlobeNewsWireOct 19, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, mult…

● GlobeNewsWireOct 15, 2026 · 06:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026…

● MarketBeatOct 2, 2026 · 19:02 ET
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

Zymeworks NASDAQ: ZYME said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a comm…

● Seeking AlphaSep 28, 2026 · 16:43 ET
Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (ZYME) M&A Call Transcript…

● GlobeNewsWireSep 28, 2026 · 06:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) --  Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, mul…

● Defense WorldSep 28, 2026 · 03:25 ETEARNINGS EXPECTED BY JAN 25
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME

Bank of America Corp DE purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund pur…

● GlobeNewsWireSep 23, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Zymeworks Completes Acquisition of Theravance Biopharma

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, mult…

● Seeking AlphaSep 14, 2026 · 19:31 ET
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Defense WorldSep 8, 2026 · 04:18 ETEARNINGS EXPECTED BY JAN 25
Jupiter Topco LLC Buys New Position in Zymeworks Inc. $ZYME

Jupiter Topco LLC bought a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought …

● Seeking AlphaAug 27, 2026 · 07:45 ET
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expa…

● Defense WorldAug 27, 2026 · 03:57 ETEARNINGS EXPECTED BY JAN 25
Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME

Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm ow…

● Defense WorldAug 24, 2026 · 03:53 ETEARNINGS EXPECTED BY JAN 25
Deutsche Bank AG Buys Shares of 397,190 Zymeworks Inc. $ZYME

Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased …

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Jan 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just ZYME · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.